HIV / AIDS in the News

Merck's Phase 3 Trial of Drug Regimen to Treat Adults With HIV-1 Meets Primary Efficacy Endpoint - marketscreener.com

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Two-drug HIV pill from Merck rivals standard treatment in trials - Stock Titan

 

Age, HIV, and Metabolic Syndrome Together Tied to Cognitive Impairment Risk - MedPage Today

 

Tacoma City Council approves funding for HIV, STI self-testing for LGBTQ+ youth - KOMO

 

Funding cuts are devastating Black HIV prevention work. But activists say pressure is working. - LGBTQ Nation

 

DOR/ISL Phase III data underlines trend for shift towards two-drug STRs in HIV - Clinical Trials Arena

 

Dual immune modulators delay, but don’t prevent, HIV rebound after stopping antiretrovirals - Aidsmap

 

Single-Dose Dolutegravir Safe in Kids With HIV Receiving Preventive TB Treatment - MedPage Today

 

New Insights Into Hypertension and MACE Reduction in HIV: Steven Grinspoon, MD - AJMC

 

Traditional Chinese Medicine Shows Promise for HIV Comorbidities - Docwire News

 

Balazs Lab Study Reveals HIV Escapes Antibody Therapy Through Predictable Paths, and Blocking Them Can Achieve Sustained Viral Suppression - Ragon Institute

 

US to end health aid to Zimbabwe after funding talks collapse - Darien Times

 

Zimbabwe rejects 'lopsided' US health aid deal over data concerns - BBC

 

CROI 2026: Neurodegeneration, the challenge of aging with HIV - bioworld.com

 

Oropharyngeal cancer is becoming more common in heterosexual men with HIV - Aidsmap

 

Catholic nuns serve on the front lines of Vietnam's shifting HIV crisis - ucanews.com

 

At-home HIV care cuts new infections by 70%, research finds - Semafor

 

Battle Lines: Drugs HIV and gangs the Pacific island paradise hit by a triple epidemic - The Telegraph

 

FDOH cannot remain silent on HIV medicine crisis | Opinion - Tallahassee Democrat

 

Breakthrough anti-HIV drug "lenacapavir" by Gilead Sciences launched in African countries - BioSpectrum Asia

 

Florida uses emergency rule to cut patients off AIDS medication - Tampa Bay Times